AKTX Akari Therapeutics plc

Akari Therapeutics plc

Biotechnology: Pharmaceutical Preparations

Health Care

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barrÃ© syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

IPO Year:

Exchange: NASDAQ

Website: akaritx.com

Recent Analyst Ratings for Akari Therapeutics plc

Date	Price Target	Rating	Analyst

See more ratings

Akari Therapeutics plc

Recent Analyst Ratings for Akari Therapeutics plc

Akari Therapeutics plc Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President & CEO Gaslightwala Abizer bought $7,120 worth of American Depositary Shares representing Ordinary Shares (6,146 units at $1.16), increasing direct ownership by 2% to 277,574 units (SEC Form 4)

President & CEO Gaslightwala Abizer bought $12,000 worth of American Depositary Shares representing Ordinary Shares (10,000 units at $1.20), increasing direct ownership by 4% to 271,428 units (SEC Form 4)

President & CEO Gaslightwala Abizer bought $18,000 worth of American Depositary Shares representing Ordinary Shares (15,000 units at $1.20), increasing direct ownership by 6% to 261,428 units (SEC Form 4)

CEO Gaslightwala Abizer was granted 45,000 units of American Depositary Shares representing Ordinary Shares, increasing direct ownership by 22% to 246,428 units (SEC Form 4)

CEO Gaslightwala Abizer was granted 20,000 units of American Depositary Shares representing Ordinary Shares, increasing direct ownership by 11% to 201,428 units (SEC Form 4)

Director Patel Sandip I was granted 44,642 units of American Depositary Shares representing Ordinary Shares, increasing direct ownership by 10% to 496,499 units (SEC Form 4)

SEC Form 4 filed by Director Bazemore Robert B

SEC Form 4 filed by Director Neal James R

SEC Form 4 filed by Director Patel Sandip I

SEC Form 4 filed by Director Prudo-Chlebosz Raymond

Akari Therapeutics plc Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

President & CEO Gaslightwala Abizer bought $7,120 worth of American Depositary Shares representing Ordinary Shares (6,146 units at $1.16), increasing direct ownership by 2% to 277,574 units (SEC Form 4)

President & CEO Gaslightwala Abizer bought $12,000 worth of American Depositary Shares representing Ordinary Shares (10,000 units at $1.20), increasing direct ownership by 4% to 271,428 units (SEC Form 4)

President & CEO Gaslightwala Abizer bought $18,000 worth of American Depositary Shares representing Ordinary Shares (15,000 units at $1.20), increasing direct ownership by 6% to 261,428 units (SEC Form 4)